Biotech firm Ascletis Pharma said ASC47, its muscle-preserving weight loss drug candidate, could boost the efficacy of the ...

(Reuters) -Pfizer said on Monday it would acquire drug developer Metsera in a deal valued at up to $7.3 billion, including ...

Pfizer said on Monday it would acquire weight-loss drug developer Metsera in a deal valued at up to $7.3 billion, including ...

An IQVIA report published earlier this year found that 43% of anti-obesity assets currently in development are orally ...

Novo NordiskNVO stock surged Thursday after its oral version of Wegovy helped patients lose a "significant" amount of weight ...

Researchers in Denmark observed a significant drop-off in anti-obesity drug usage after 1 year in first-time users.

Among 77,310 adults without diabetes who began taking semaglutide after it was approved for weight loss, 40,262 (52%) were no ...

Limiting coverage might look like a budget fix in the short term, but it will increase long-term costs by exacerbating preventable complications.

The new class of anti-obesity drugs, glucagon-like peptide-1 receptor agonists (GLP-1RAs), is proving remarkably effective at ...

Scientists discovered that people taking weight loss medications regained pounds weeks after they stopped taking the drugs. More than 1,000 people participated in a study and their lifestyle habits ...